Eurofins Central Laboratory Expands US Lab Operations to Eurofins Campus in Lancaster, PA

Eurofins Central Laboratory is pleased to announce that is has achieved an important strategicmilestone with the expansion and relocation of its U.S. Central Laboratory Operations to the330,000 square foot Eurofins Pharma Services campus in Lancaster, PA. The consolidation ofthe Central Laboratory into the Lancaster Laboratories campus, combined with the recentlyannounced acquisitions of leading bioanalytical, discovery, genomic and diagnostic laboratoriesin the US, positions Eurofins as a leading full service laboratory provider to the pharmaceuticaland biotech industries. This purpose built Central Laboratory is essential to the Eurofins CentralLaboratory global footprint of wholly-owned laboratory facilities in the United States, Europe,Asia and China.

Dr. Charles J. DiComo, Vice President & General Manager, U.S. & Global Laboratory Operations, explains: “The Central Laboratory in Lancaster is fully harmonized and seamlessly aligned with our other Eurofins Central Laboratories. All laboratory equipment, analytical methods, standard operating procedures and quality standards are identical across laboratories to support clinical trials being conducted across regions by our clients. Operating in line with both GLP and GCP standards, and with a strong expertise in biomarker analysis, we are positioning ourselves to become the first-choice Central Laboratory for our pharmaceuticalsponsors.”

Successfully operational since early April, the Eurofins Central Laboratory in Lancaster offers a full package of safety and esoteric testing. Furthermore, this location houses the Microbiology Center of Excellence for Eurofins Central Laboratory. The facility is accredited by thePennsylvania Department of Health, CAP, CLIA and NGSP Level I.